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Abstract
Background: Our previous study reported that microRNA-26a (miR-26a) inhibited tumor progression by inhibiting
tumor angiogenesis and intratumoral macrophage infiltration in hepatocellular carcinoma (HCC). The direct roles of
miR-26a on tumor cell invasion remain poorly understood. In this study, we aim to explore the mechanism of miR-
26a in modulating epithelial-mesenchymal transition (EMT) in HCC.
Methods: In vitro cell morphology and cell migration were compared between the hepatoma cell lines HCCLM3
and HepG2, which were established in the previous study. Overexpression and down-regulation of miR-26a were
induced in these cell lines, and Western blot and immunofluorescence assays were used to detect the expression
of EMT markers. Xenograft nude mouse models were used to observe tumor growth and pulmonary metastasis.
Immunohistochemical assays were conducted to study the relationships between miR-26a expression and enhancer
of zeste homolog 2 (EZH2) and E-cadherin expression in human HCC samples.
Results: Down-regulation of miR-26a in HCCLM3 and HepG2 cells resulted in an EMT-like cell morphology and
high motility in vitro and increased in tumor growth and pulmonary metastasis in vivo. Through down-regulation
of EZH2 expression and up-regulation of E-cadherin expression, miR-26a inhibited the EMT process in vitro and in
vivo. Luciferase reporter assay showed that miR-26a directly interacted with EZH2 messenger RNA (mRNA).
Furthermore, the expression of miR-26a was positively correlated with E-cadherin expression and inversely
correlated with EZH2 expression in human HCC tissue.
Conclusions: miR-26a inhibited the EMT process in HCC by down-regulating EZH2 expression.
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Background
Liver cancer (mostly hepatocellular carcinoma [HCC]) is
the sixth most prevalent cancer worldwide [1], and it is
the second most frequent cause of cancer-related death
in men and the sixth most frequent in women [2]. Surgi-
cal resection provides a cure in only about 20–30 % of
HCC patients, and the reported 5-year survival rate is
40–50 %, with a high incidence of postoperative recur-
rence [3, 4]. Postoperative recurrence remains a major
problem in reducing patient survival [5], and it may
occur because of intrahepatic metastasis from the ori-
ginal primary tumor even for the patients with early-
stage cancer [3] or from de novo carcinogenesis [6]. The
precise mechanisms involved in metastasis are still not
well understood, but accumulating evidence suggests
that an epithelial-mesenchymal transition (EMT)-like
process plays a major role [7]. EMT is a transient and
reversible switch from a polarized and epithelial pheno-
type to a fibroblastoid or mesenchymal cellular pheno-
type, with the latter showing highly motile and invasive
properties [8, 9]. In general, this process is a fundamen-
tal event both in the early stage of embryonic develop-
ment and in pathophysiological situations, including
wound healing, chronic inflammation, and carcinoma
progression [7]. Several studies have reported that func-
tional loss or down-regulation of E-cadherin is a hall-
mark of EMT [10, 11], and transcriptional control of E-
cadherin during EMT seems to be required. Although
EMT entails the down-regulation of other epithelial-
specific genes, such as those for components of tight
and gap junctions or desmosomes, E-cadherin down-
regulation is thought to be inherent to EMT [12].
MicroRNAs (miRNAs) are an evolutionarily conserved
family of small (a class of 22-nucleotide) noncoding
RNAs, known to be potent modifiers of gene expression
at a posttranscriptional level. They regulate multiple cel-
lular processes such as tumorigenesis and metastasis by
down-regulating gene expression in various malignan-
cies, including HCC [13]. microRNA-26a (miR-26a), a
member of the miR-26 family, has been considered to be
a potential tumor suppressor in HCC [14, 15]. miR-26a
has been reported to suppress tumor growth and metas-
tasis of HCC through the interleukin (IL)-6-Stat3 signal-
ing pathway [16], and down-regulation of miR-26a in
tumor tissue was associated with poor overall survival
for patients who underwent curative surgery for HCC
[17]. In our previous study, we found that miR-26a indir-
ectly suppresses tumor progress in HCC by inhibiting
tumor angiogenesis and suppressing intratumoral
macrophage infiltration [14, 18]. However, how miR-26a
modulates tumor progression in a direct manner re-
mains poorly understood. It was reported that miR-26a
mediated E-cadherin expression, the hallmark of EMT,
in oral tongue squamous cell carcinoma, and the
enhancer of zeste homolog 2 (EZH2) was the presumed
key molecule that mediated miR-26a-induced down-
regulation of E-cadherin expression [19]. However, whether
miR-26a plays a crucial role in EMT regulation and its
underlying mechanism in HCC remains unknown. In the
present study, we aimed to investigate the functional role of
miR-26a in EMT and consider its potential as a therapeutic
target in HCC.
Results
Down-regulation of miR-26a is associated with EMT in
tumor cells
In our previous study [18], the expression levels of miR-
26a were modified in two human hepatoma cell lines,
HepG2 and HCCLM3, and subclones with stable expres-
sion of miR-26a were established. These subclones were
HepG2-wt (wild type of HepG2), HepG2-control (HepG2
transfected with the negative control of precursor miRNA),
and HepG2-miR-26a (HepG2 transfected with pre-miR-26a),
and HCCLM3-wt (wild type of HCCLM3), HCCLM3-
control (HCCLM3 transfected with the negative control of
anti-miRNA-LNAs), and HCCLM3-anti-miR-26a (HCCLM3
transfected with anti-miRNA-LNAs against miR-26a). The
HCCLM3-anti-miR-26a cells gained an EMT-like phenotype
compared with HCCLM3-control cells, showing an irregular
fibroblast-like shape instead of a typical epithelial cobblestone
appearance; HepG2-miR-26a cells had no morphological
changes compared to HepG2-control cells (Fig. 1a). In the
cell migration assay, HepG2-control cells exhibited signifi-
cantly higher migration potential than HepG2-miR-26a cells,
while HCCLM3-anti-miR-26a cells exhibited significantly
higher migration potential than HCCLM3-control cells
(Fig. 1b). Western blot (Fig. 1c) and immunofluorescence as-
says (Fig. 1d) demonstrated that miR-26a up-regulated the
expression of epithelial cell marker E-cadherin and down-
regulated the expression of the mesenchymal cell markers
N-cadherin and vimentin. These results indicate that down-
regulation of miR-26a induced EMT in HCC cells.
miR-26a regulated EMT by targeting EZH2
Overexpression of EZH2 has been found to correlate
with tumor aggressiveness, metastasis, and poor progno-
sis in numerous cancer types [20, 21], including HCC
[22]. miR-26a was reported to suppress tumor growth by
targeting EZH2 in some tumors [23, 24]. To explore the
mechanisms of miR-26a in moderating tumor growth
and metastasis of HCC tumors, several assays were
performed. Western blot analysis showed that EZH2 ex-
pression was decreased after transfection with pre-miR-
26a in HepG2 cells and increased after down-regulation
of miR-26a in HCCLM3 cells compared to respective
controls, while the expression of E-cadherin showed the
opposite results (Fig. 2a). Moreover, luciferase reporter
assay was performed to determine whether miR-26a
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directly regulated EZH2 expression in HCC cells. The
target sequence of EZH2 3′UTR (wt 3′UTR), which
contained a miR-26a putative binding site, could be mu-
tated, or a mutant sequence (mt 3′UTR) messenger
RNA (mRNA) was cloned downstream of the luciferase
reporter gene vector (Fig. 2b). A significant decrease of
luciferase activity was observed when the cells were
transfected with miR-26a compared to the control
(Fig. 2c, left). The activity of the mt 3′UTR vector was
unaffected by a simultaneous transfection with miR-26a
(Fig. 2c, right). These results suggest that miR-26a dir-
ectly interacted with EZH2 mRNA and inhibited the ex-
pression of EZH2.
Because EZH2 reportedly down-regulates E-cadherin
expression [19, 25], we transfected our two HCC cell lines
with EZH2 small interfering RNA (siRNA) to explore
whether miR-26a could regulate E-cadherin expression by
directly targeting EZH2 expression. The results show that
EZH2 siRNA reduced E-cadherin expression and elimi-
nated the difference in E-cadherin expression between
HepG2-control and HepG2-miR-26a (Fig. 2d, left) and be-
tween HCCLM3-control and HCCLM3-anti-miR-26a
(Fig. 2d, right).
miR-26a inhibited tumor growth and EMT in vivo
To explore the role of miR-26a in tumor growth and
metastasis, orthotopic nude mouse models were estab-
lished with HepG2 and HCCLM3 cell lines. Mice with
HCCLM3-anti-miR-26a tumors had lower body weights
(18.6 ± 2.3 vs 21.2 ± 1.5 g 36 days after model establish-
ment, P = 0.037) and larger tumors (973.5 ± 334.2 vs
515.6 ± 165.4 mm3, P = 0.019, Fig. 3a) than those with
HCCLM3-control tumors. Mice with HepG2-miR-26a tu-
mors had a higher body weight (19.9 ± 2.4 vs 16.7 ± 1.0 g
36 days after model establishment, P = 0.026) and smaller
tumors (252.6 ± 98.1 vs 393.7 ± 107.5 mm3, P = 0.039,
Fig. 3b) compared to those with HepG2-control tumors.
Moreover, more pulmonary metastatic foci occurred in
the HCCLM3-anti-miR-26a group than in the HCCLM3-
control group (6.8 ± 1.7 vs 2.3 ± 1.0, P = 0.001, Fig 3c),
Fig. 1 Down-regulation of miR-26a induced EMT in hepatoma cells in vitro. a Morphologic changes consistent with EMT (spindle-shaped cells
with loss of polarity and increased intercellular separation) were observed in the HCCLM3-anti-miR-26a cells compared to control cells; HepG2
cells did not show morphological changes. b Cell migration through a Transwell chamber was compared between hepatoma cells transfected
with miR-26a and control. The number of migrated cells was evaluated by counting 10 random fields at ×100 magnification. Western blot (c) and
immunofluorescence assays (d) showed that down-regulation of miR-26a resulted in down-regulation of E-cadherin and up-regulation of N-cadherin
and vimentin
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which was shown in both bright field (b) and fluores-
cence (f ) imaging. No pulmonary metastases were
detected in the mouse models established with
HepG2, a hepatoma cell line without potential for
lung metastasis [26], including HepG2-miR-26a and
HepG2-control cells (Fig. 3c). We further examined
the expression of E-cadherin, N-cadherin, and vimen-
tin in the orthotopic tumor samples. In the HCCLM3
groups, immunohistochemistry revealed typical mem-
branous E-cadherin expression in the cell-cell con-
tacts in the HCCLM3-control group, with low
expression of N-cadherin and vimentin. In contrast,
HCCLM3-anti-miR-26a tumors showed a significant
reduction of E-cadherin expression, with up-regulated
expression of N-cadherin and vimentin (the area of
positive staining, 17,245.5 ± 5560.9 vs 41,578.8 ±
8220.3; 90,067.7 ± 12,891.1 vs 36,617.1 ± 5303.3;
27,053.1 ± 3910.9 vs 11,537.5 ± 2455.4; P < 0.05 for all,
Fig. 3d). In the HepG2 groups, higher expression of
E-cadherin and lower expression of N-cadherin and
vimentin were found in the HepG2-miR-26a group in
comparison to those in the HepG2-control group (the
area of positive staining, 89,588.7 ± 10,305.1 vs
39,017.3 ± 6326.9; 18,865.1 ± 3244.4 vs 88,272.7 ±
9656.7; 16,910.5 ± 3601.1 vs 45,127.5 ± 3593.1; P < 0.05
for all, Fig. 3d). These results indicate that miR-26a sig-
nificantly inhibited tumor growth and lung metastasis in
vivo, along with down-regulating EMT-related makers.
Furthermore, in HCCLM3-control tumors, the expression
of EZH2 was lower than that in HCCLM3-anti-26a tumors
(the integrated optical density [IOD] of positive staining,
13,744.9 ± 2210.5 vs 30,349.9 ± 4671.7, P < 0.005,
Fig. 3d). In the HepG2 groups, the expression of
EZH2 in HepG2-control group was significantly
higher than that in the HepG2-miR-26a group (the
IOD of positive staining, 26,594.3 ± 3067.9 vs 13,511.8
± 2319.9, P < 0.005, Fig. 3d). These results indicate
that miR-26a expression inhibited tumor progression
Fig. 2 EZH2 played a critical role in miR-26a modulating EMT process. a Western blot assay showed that miR-26a down-regulated EZH2 expression
and up-regulated E-cadherin expression. b Diagram of the putative binding sequence of miR-26a in the 3′-UTR containing reporter constructs of EZH2
is shown. c Luciferase reporter assays showed that miR-26a significantly decreased the luciferase activity of wild-type EZH2 but not mutant EZH2. NC,
the mock of precursor miRNA, *P < 0.05 compared with control. d EZH2 siRNA transfection in HCC cells eliminated the difference in E-cadherin miR-26
overexpression and down-regulation
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in vivo and targeting EZH2-related EMT process may
have been one of the main mechanisms.
miR-26a expression was consistent with E-cadherin
expression and inversely correlated with EZH2 expression
in human HCC tissue
To investigate the relationships between miR-26a ex-
pression and E-cadherin or EZH2 expression, we exam-
ined miR-26a expression in 52 HCC patients from 67
HCC patients with expression of E-cadherin and EZH2.
miR-26a expression data were obtained in our previous
study [17]. Representative images of immunostaining for
E-cadherin are shown in Fig. 4a. E-cadherin expression
was found to be positively associated with miR-26a ex-
pression (R = 0.462, P = 0.001, Fig. 4b). Using a median
value of miR-26a expression as a cutoff point, we divided
the 52 cases of HCC patients into two groups. Patients
with high miR-26a expression had significantly higher E-
cadherin expression compared with those with low miR-
26a expression (the area of positive staining, 352,159.7 ±
108,722.0 vs 264,432.9 ± 91,518.7 P = 0.003, Fig 4c). In
addition, EZH2 expression (Fig. 4d) was found to be in-
versely associated with miR-26a expression (R = −0.472,
P = 0.001, Fig. 4e). Patients with high miR-26a expres-
sion had significantly lower EZH2 expression than those
with low miR-26a expression (the area of positive staining,
148,246.9 ± 115,257.0 vs 231,286.3 ± 79,644.3, P = 0.004,
Fig. 4f). The results further support an inverse relationship
between miR-26a and EZH2 expression in human HCC
tissue.
Discussion
miR-26a plays a critical role in various types human can-
cers [17, 27, 28]. Although some studies have shown that
it may function as an oncogene in malignant glioma,
lung cancer, cholangiocarcinoma, and chronic lympho-
cytic leukemia [29–31], emerging evidence demonstrates
that miR-26a may serve as a potential tumor suppressor
in other malignant tumors [17, 32–35]. Previous study
showed that miR-26a was down-regulated in HCC
tumor samples with a poor prognosis, while high levels
of miR-26a expression were associated with a good prog-
nosis for patients who underwent curative liver resection
[17]. Moreover, our previous study found that miR-26a
inhibited HCC tumor growth and metastasis by modu-
lating tumor microenvironment (e.g., inhibiting the
Fig. 3 miR-26a inhibited EMT process in vivo. a, b HCC subcutaneous tumor tissues (HCCLM3-control, HCCLM3-anti-miR-26a, HepG2-control, and
HepG2-miR-26a) were implanted into nude mouse livers to establish the xenograft HCC models. Thirty-five days after implantation, the mice were
euthanized, and their body weights and tumor volumes were assessed. c Quantification of bioluminescence of lung metastatic foci showed that
down-regulation of miR-26a significantly accelerated pulmonary metastasis (arrows indicate metastatic foci in lung). HCCLM3-anti-miR-26a and
HCCLM3-control tumors were compared by both bright field (b) and fluorescence (f) imaging. No pulmonary metastases occurred in HepG2-control
xenografts and HepG2-miR-26a (up-regulation miR-26a) xenografts based on quantification of bioluminescence. d Immunohistochemistry revealed that
E-cadherin expression was decreased and the expression level of N-cadherin and vimentin was increased in HCCLM3-anti-miR-26a tumors compared
to HCCLM3-controls. In HepG2-miR-26a tumors, EMT markers were inhibited compared to HepG2-controls. In addition, EZH2 expression was inversely
correlated with expression of E-cadherin in HCCLM3 and HepG2 tumors. Representative images are shown at ×200. *P < 0.05 compared to control
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Fig. 4 The relationships between miR-26a expression and the expression of EZH2 and E-cadherin in human HCC tissue. a A HCC tissue microarray
was used to analyze E-cadherin expression using immunohistochemistry. Representative images are shown (×200). b miR-26a was positively associated
with intratumoral E-cadherin expression (R = 0.462, P = 0.001). c Patients with high miR-26a expression had significantly higher E-cadherin expression
compared with those with low miR-26a expression (P = 0.003). d Representative images of EZH2 staining are shown (×200). e An inverse association
between miR-26a and EZH2 expression were found (R=−0.472, P= 0.001). f Patients with high miR-26a expression had significantly lower EZH2 expression
compared with those with low miR-26a expression (P= 0.004)
Ma et al. Journal of Hematology & Oncology  (2016) 9:1 Page 6 of 10
tumor angiogenesis [15] and macrophage infiltration
[14]). However, the underlying mechanisms associated
with miR-26a in HCC invasion are still not fully under-
stood. Here, we first demonstrated that miR-26a inhibits
the EMT process by regulating EZH2 expression in
HCC through a cell-autonomous mechanism (Fig. 5).
Metastasis and tumorigenesis compose a multi-step
process [36], and a considerable amount of evidence in-
dicates that EMT is responsible for converting noninva-
sive tumor cells into cells with metastatic potential,
enabling invasion into the basement membrane and the
vascular system, survival in the circulation, and extrava-
sion at a distant secondary site [7, 37]. In addition, EMT
has been demonstrated to significantly contribute to
liver fibrosis, which provides a pre-metastatic niche or
metastatic-supportive microenvironments [7, 38–40].
Various studies have demonstrated the critical role of
miRNAs in EMT through regulation of E-cadherin ex-
pression [41, 42]. Moreover, some reports have found
that miR-26a strongly reduces the expression of EZH2
in some tumors [23, 34, 43]. EZH2 is one catalytic sub-
unit of the polycomb repressive complex 2, a transcrip-
tional repressor of target genes. Overexpression of EZH2
was found to correlate with tumor aggressiveness, metas-
tasis, and poor prognosis in numerous cancers [20, 21],
including HCC [22, 44]. Furthermore, EZH2-mediated E-
cadherin expression in some tumors [19, 45]. In the
present study, miR-26a was found to be inversely corre-
lated with EZH2 expression in the HCC cells and HCC
tissues, and overexpression of miR-26a decreased the lu-
ciferase reporter activity of the wild-type 3′-UTR of EZH2
but not the mutant 3′-UTR. More importantly, the effects
of miR-26a modulation on EMT in HCC were affected by
the EZH2 siRNA. The data support that miR-26a could
inhibit EMT by repressing the expression of EZH2. These
results accord with findings in nasopharyngeal and oral
squamous cell carcinomas [19, 23–25].
This study has some potential limitations. Our re-
sults showed that miR-26a inhibited EMT through
targeting EZH2 expression. However, they did not ex-
clude other signal pathways that may modulate EMT
and could be mediated by miR-26a. Our preliminary
study did not explore the effect of the HCC environ-
ment on miR-26a or EMT.
Since EMT has been critically discussed as the key
process in tumor aggressiveness and metastasis [46], our
findings in the present study demonstrate that miR-26a
as a suppressive miRNA could inhibit tumor metastasis
and invasion partly by impeding EMT through repres-
sion of EZH2. The data also suggest that miR-26a could
be a marker and potential therapeutic target in HCC
patients in the future.
Conclusions
In conclusion, in view of the anti-invasive effects of
miR-26a on tumor cells, therapeutic miR-26a delivery in
the treatment of HCC deserves further investigation.
Methods
Cell line culture and morphological observation
The human HCC cell line HepG2 cells (obtained from
the Cell Bank of the Chinese Academy of Sciences,
Shanghai, China) and HCCLM3 cells [47] (human HCC
cell lines with high metastatic potential, established at
Liver Cancer Institute, Fudan University, Shanghai,
China) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Carlsbad, CA) containing
10 % fetal bovine serum (FBS) and 100 U ml−1 penicillin
and 50 mg ml−1 streptomycin. All cells were incubated
at 37 °C with a humidified atmosphere of 5 % CO2. The
morphology of the HCC cells was observed using phase
microscopy (Leica).
miRNA and transfection
As described in our previous study [18], to modify miR-
26a expression levels in HCC cell lines, we obtained re-
combinant lentivirus vectors from Genechem (Shanghai,
China) that included genes such as pre-miR-26a, the
negative control precursor miRNA; anti-miRNA-locked
nucleic acids (LNAs) against miR-26a; and the negative
control of anti-miRNA-LNAs. These vectors, with their
packaging vectors, were transfected into 293 T cells
Fig. 5 The proposed molecular mechanism was shown in a diagram
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using Lipofectamine 2000 (Invitrogen). HepG2 cells or
HCCLM3 cells were then transfected with virus follow-
ing the manufacturer’s instructions, and Western blot
and quantitative RT-PCR (qRT-PCR) were used to valid-
ate the transfection results.
Western blot
Cells were lysed using cell lysis buffer (150 mM NaCl,
50 mM Tris-HCl, pH 8.0, 0.1 % SDS, 1 % Triton X-100)
containing protease and phosphatase inhibitors. Equiva-
lent amounts of whole cell extracts were subjected to
SDS-PAGE gel and transferred to nitrocellulose mem-
branes. The membranes were blocked with 5 % nonfat
milk for 2 h and then incubated with the respective pri-
mary antibody overnight at 4 °C, followed by the incuba-
tion of the appropriate HRP-conjugated secondary
antibody for 2 h at room temperature. Blots were visual-
ized with an ECL detection kit (Pierce, IL) and analyzed
using Quantity One 1-D Analysis Software (Bio-Rad, San
Francisco, CA).
Cell migration assay
Quantitative cell migration assays were performed using
a chamber (Corning, Tewksbury. MA) with 8.0-μm poly-
carbonate filter inserts in 24-well plates as described be-
fore [18]. About 1 × 105 cells per well were added to the
upper chamber, and the lower chamber was filled with
cell medium. Cells were allowed to migrate for 24 h at
37 °C. Non-migrated cells were removed from the upper
chamber using a cotton swab, and the migrated cells
were fixed with methanol, stained with crystal violet,
and photographed under an inverted microscope. Migra-
tion was assessed by counting the number of stained
cells from five random fields at ×200 magnification.
Luciferase activity assay
HEK293T cells were seeded in a 96-well plate at 50 to
60 % confluence. After 24 h, cells were transfected with
50 ng of miR-26a expression vector, miR-26a inhibitor,
control vector, or negative control. Cells were co-
transfected with 10 ng of the wild-type (WT) or mutant
3′UTR of the target gene. Transfections were performed
using 0.45 μl of Fugene (Promega, Madison, WI). Forty-
eight hours after transfection, cells were collected and
Renilla luciferase activity was measured using a dual-
luciferase reporter system (Promega) and detected using
an Orion II microplate luminometer (Berthold, Bad
Wildbad, Germany). Luciferase reporter assays were per-
formed in quadruplicate and repeated in three independ-
ent experiments.
Xenograft model of HCC in nude mice
Male BALB/c nude mice (5 weeks old, weighting 18–20 g)
were purchased from the Shanghai Institute of Materia
Medica (Chinese Academy of Science) and housed under
specific pathogen-free conditions. The experimental proto-
col was approved by the Shanghai Medical Experimental
Animal Care Commission. The various cells (6 × 106 cells)
in normal saline were implanted by subcutaneous injection
(200 μl per mouse) to obtain the subcutaneous tumors.
The mice were euthanized after 4 weeks to obtain the
tumor tissues, which were used in the orthotopic model.
The xenograft HCC model was established by orthotopic
implantation of histologically intact tumor tissue into the
nude mouse liver in the previous literature [48]. The body
weights of mice were measured by electronic balance every
week. Five weeks later, the mice were euthanized and their
body weights were compared using independent-sample t
test. After their volume was measured, the tumors (re-
moved from liver) were placed in a 4 % paraformaldehyde
solution. The tumor volume was calculated according
to the formula: tumor volume = (largest diameter ×
perpendicular height2)/2.
Patients, specimens, and follow-up
In this study, HCC specimens used in the immunohisto-
chemical assay were obtained randomly from patients
who underwent radical resection of pathologically con-
firmed tumors from 1999 to 2003 at the Liver Cancer In-
stitute and Zhongshan Hospital (Fudan University,
Shanghai, China); these specimens have been described
previously [14, 17, 18]. No patients received any preopera-
tive anticancer treatment. The present research was ap-
proved by the research ethics committee of Zhongshan
Hospital. A total of 67 cases were used in this study to
examine EZH2 expression, with 52 of the 67 HCC patients
expressing miR-26a. The miR-26a expression data were
obtained from our previous study. All patients included
were followed up until 2011, with a median observation
time of approximately 60 months. All patients provided
written informed consent to participate in this study.
Statistical analysis
Data analysis was performed using SPSS 19.0 for Win-
dows (SPSS Inc. Chicago, IL). Unpaired Student’s t test
or Pearson’s correlation test was used to compare quan-
titative variables. P < 0.05 was considered statistically
significant.
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